Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Most clear post of the day and aligns with what I generally think as well. You said it well.
I agree with everything you said too.
Relatively ugly CWEB numbers and you're right - alarming cash position with higher debt.
I hope CVSI can manage its finances well so as to keep holding on through the choppiness for the next few quarters and until FDA issues some guidelines.
If CWEB continues its path, CVSI will look like the responsible party that can actually run a business.
Then when FDA issues guidelines, CVSI can roll out its high performing products (ingestibles) into the major retailers that right now, due to lack of FDA guidelines, only allow the low selling products (topicals).
Looking for feedback - I will say this about CVSI: I'm long and think they have a great product and are doing everything right for the medium and long term. However, their marketing stinks. Their brand has no public story, there's no real cohesion around the brand, the logo is lacking, the plusCBD brand lacks meaning and recognition.
For example: They could just make the + sign larger and build the brand around the + and the + could represent how CBD adds to your life, to your performance, to your health. And they could really lean into the + sign. Then you tell that single story, nationwide, in all mediums and bam, there's meaning to the brand.
Regardless, their marketing and brand stinks from a consumer standpoint.
They need help asap because right now, while they are still one of the leaders simply due to shelf space not brand recognition, is the time to push their advantage.
Anyone have any thoughts on this?
100% Agree. You have to be utterly stupid to keep your business headquartered in California. They should move asap and realize those savings.
Good point. $6 I'd be happy with but not excited. $8+ I get excited.
Same article came out a few months ago. Said the same exact stuff.
I'd be happy if they bought CVSI at a premium due to sales probably exploding once FDA issues rules and CVSI can put their digestables on the shelves of their current large retailers where they can only sell topicals right now. Also a NASDAQ uplisting would also boost price.
The distribution work, industry brand building work, advocacy work and product development work CVSI has done is incredibly valuable.
But who knows what Aurora's leadership is like.
Trying to get CVSI on the cheap with strict present fundamentals I don't think would work because there is too much runway being laid out for the industry right now.
But if they are like tech companies, willing to pay a good premium - then I'm all for it.
I'd be happy with $6-$12 buyout. But at this current stock price, it's hard to see a higher end $10-$12 buyout.
There's no way a buyout happens below $4.00.
What are your thoughts?
A whopping 21 views - let's hope they actually market this video to industry influencers.
Great news but I thought the FDA said no one could market CBD as a 'dietary supplement' but CV refers to them as such in this new press release.
“We are excited to further expand availability of our topicals and award-winning dietary supplements in the food, drug and mass retail channel through our new partnership with Southeastern Grocers, one of the largest supermarket companies in the U.S.,” added Dowling. “Following our initial launch, we anticipate additional distribution gains across the Winn-Dixie and BI-LO banners and new distribution with SEG’s other leading retail banners.”
I thought the FDA said no one could market CBD as a 'dietary supplement' but CV refers to them as such in this new press release.
“We are excited to further expand availability of our topicals and award-winning dietary supplements in the food, drug and mass retail channel through our new partnership with Southeastern Grocers, one of the largest supermarket companies in the U.S.,” added Dowling. “Following our initial launch, we anticipate additional distribution gains across the Winn-Dixie and BI-LO banners and new distribution with SEG’s other leading retail banners.”
Cantor Fitzgerald initiates CVSI coverage at $4.20 target with "Overweight" rating
https://seekingalpha.com/news/3517133-cantor-likes-cv-sciences-premarket-analyst-action
Exactly - what does this mean for CVSI? I'm emailing IR.
You're not entirely wrong here but I'm going to guess they come in low as well.
The barrage of national media slamming the CBD industry as unsafe, unregulated and can cause health problems (falsely and out of context) did a lot of damage.
The media, coupled with the 1,000 new scam brands will hurt CW I'm assuming too.
You are right. They should definitely have:
- Loyalty program
- Revamp e-commerce
- A big overhaul in how they market their product to consumers. Hire a real advertising/PR firm.
They need to move on these fast - now is the time to start building loyalty, educating consumers and hitting marketing hard to build brand awareness while they are still on top.
Agree with you. I don't think any real buying will start up again for a few days-2 weeks as people wait for it to bottom out. I think it'll drift towards $1 on no news until the FDA releases guidelines.
With Q4 already forecasted, no catalysts until FDA.
Next catalyst is FDA and/or Q4 earnings. I don't think any distribution deal announcements move the stock that much anymore at this point.
I thought it would be worse. However, I can see it drifting down towards a buck as there is nothing for anyone to do at this point but wait for the FDA, since they already forecasted Q4 - which will look the same as this Q.
If we close today above $1.50 that's a big win in my book. The only thing that will save us rest of year is if FDA issues guidelines and regulations. Once FDA issues, it'll be a big boost across the whole sector then if CVSI can put products that people really want, in all their existing big chains, we are good.
The topicals are ridiculous - does anyone actually even buy those? People want ingestibles but the big chains won't allow them in until FDA issues - only topicals.
If $1.80 is your worst case, I'll take that. I see it heading to $1.50, if not lower. Won't be surprised if we hit $1.20 tomorrow, intraday.
I'm long CVSI and have always said my timeline was 1-3 years (said it a year ago when I entered too).
However, IMO tomorrow will be a bloodbath.
No matter what is baked in, the shock of such a dramatically lower earnings report will hit it hard.
Hopefully it recovers back to where we are - $2.00'ish.
It's going to be a rocky next 1-3 quarters as CVSI learns how to deal with the big increase in competition in various forms.
Listening to call. I feel good with the progress of the company.
This is the short-term choppiness Joe referenced. They are moving forward well on all fronts.
However, short term, this is going to be a bloodbath. I'll pick some more shares up at $1.00, or even $0.50.
Phase 1 clinical trials for their cbd drug in first half of 2020. Joe (CEO) says VERY optimistic on this product.
Clearly lowballing and putting all bad news in with this bad news in the HOPES that they over-perform. Let's certainly HOPE lol.
Until regulatory becomes clear, this whole industry is a mess.
Part of the problem is that it has been nothing but negative nationwide press this quarter with everyone saying it could be fraudulent CBD, no regulatory controls, some people got sick etc.
This press was definitely a contributing factor in people buying less.
I guess this is what Dowling meant by 'choppy' in last quarter's call.
After hours means nothing on OTC. Completely irrelevant.
I'm long and this quarter is a hard one to swallow.
How is it a scam? It's very transparent. They make a product and sell it in stores and this quarter stunk. What's a scam about it?
Smart play.
NEWS: CVSi says in 6,000+ stores in new press release
Here's the press release applauding the USDA's new US domestic hemp production program. In it they say they are in over 6,000 stores now at the bottom in the "About CV Sciences" section:
https://ir.cvsciences.com/press-releases/detail/140/cv-sciences-inc-applauds-usdas-establishment-of-the
CV SCIENCES, INC. APPLAUDS USDA’S ESTABLISHMENT OF THE U.S. DOMESTIC HEMP PRODUCTION PROGRAM
October 30, 2019
Program Creates a Consistent Regulatory Framework for Hemp Production Throughout the United States
SAN DIEGO, Oct. 30, 2019 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, is pleased to announce its support of the U.S. Department of Agriculture’s (USDA) progress on implementation of the hemp provisions of the 2018 Farm Bill. On October 29, 2019, U.S. Secretary of Agriculture Sonny Perdue announced the interim final rule for the U.S. Domestic Hemp Production Program. USDA regulation of hemp farming provides a consistent regulatory framework that supports responsible and sustainable hemp production in the United States. A strong USDA regulatory framework is needed to differentiate hemp, an agricultural commodity, from marijuana, a controlled substance, and to protect farmers and consumers.
USDA announced that later this week, an interim final rule formalizing the program will be published in the Federal Register. This will allow hemp to be grown under federally-approved plans and make hemp producers eligible for agricultural programs, like crop insurance. The rule includes provisions for USDA to approve hemp production plans developed by states and Indian tribes including: requirements for maintaining information on the land where hemp is produced; testing the levels of THC to ensure compliance with the law; disposing of noncompliant plants; and licensing requirements.
“We are eager to see full implementation of USDA’s Hemp Production Program,” said Joseph Dowling, Chief Executive Officer of CV Sciences. “The hemp industry is poised for rapid growth that will create new jobs and economic development opportunities for farmers, rural communities and the CBD industry. Regulatory clarity is critical for the hemp industry and we believe the interim final rule is another step toward the proper regulatory framework that will help unlock the true domestic growth potential of the industry. We’d like to thank the U.S. Hemp Roundtable and its hemp industry members for their tireless efforts in achieving this milestone. Now that hemp farming regulations have been established it’s time to focus on FDA’s work to clarify the regulatory pathway for hemp-derived CBD products in dietary supplements. USDA and FDA regulation of hemp and CBD will provide a level playing field for quality and science-based CBD companies to operate, and allow consumers access to safe and beneficial products.”
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors; and a drug development division focused on developing and commercializing CBD-based novel therapeutics utilizing CBD. The Company’s PlusCBD™ Oil products are sold at more than 6,000 retail locations through the U.S. and it is the top-selling brand of hemp-derived CBD on the market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. CV Sciences’ state-of-the-art facility follows all guidelines for Good Manufacturing Practices (GMP) and the Company’s full spectrum hemp extracts are processed, produced, and tested throughout the manufacturing process to confirm the cannabinoid content meets strict company standards. With a commitment to science, PlusCBD™ Oil’s benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. PlusCBD™ Oil was the first hemp CBD supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. CV Sciences, Inc. has primary offices and facilities in San Diego, California. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
CONTACT INFORMATION:
Investor Contact:
ICR
Scott Van Winkle
617-956-6736
scott.vanwinkle@icrinc.com
Media Contact:
ICR
Cory Ziskind
646-277-1232
cory.ziskind@icrinc.com
This must be a fake post meant to mislead - it's nonsensical.
What are you talking about? Please provide a link if what you are saying is even true.
Bought more - stupidest article by Zacks you can imagine. I'd bet 90% that an algorithm wrote that article, not an actual human. It's just regurgitated stuff, nothing new.
When an article contains this: "An earnings beat or miss may not be the sole basis for a stock moving higher or lower." you have to guess a human didn't write it.
Hopefully the FDA sets some strict guidelines and CVSI and a few others make the cut and all these other scammy clowns with "CBD companies" that aren't actually real companies, nor take any of the professional precautions or know what even is in their bad product - get run out or are shut down.
I'm so sick of hearing about xyz person started a CBD company. Get these clowns who don't know what their product actually is, out of the marketplace.
CVSI Nov. 5th Q3 results release
CV SCIENCES, INC. TO ANNOUNCE THIRD QUARTER 2019 RESULTS ON NOVEMBER 5, 2019
https://ir.cvsciences.com/press-releases/detail/137/cv-sciences-inc-to-announce-third-quarter-2019-results-on
October 23, 2019
SAN DIEGO, Oct. 23, 2019 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will release financial results for its third quarter 2019 ended September 30, 2019, after the stock market closes on Tuesday, November 5, 2019. The Company will hold a conference call with the investment community at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) that same day.
The webcast of the conference call will be available on the Investor Relations section of the Company's website at https://ir.cvsciences.com/news-events and at http://public.viavid.com/index.php?id=136763. The webcast will be archived for approximately 30 days.
Investors interested in participating in the live call can also dial (877) 407-0784 from the U.S. or international callers can dial (201) 689-8560. A telephone replay will be available approximately two hours after the call concludes and will be available through Tuesday, November 12, 2019, by dialing (844) 512-2921 from the U.S. or (412) 317-6671 from international locations, and entering confirmation code 13695960.
About CV Sciences, Inc.
CV Sciences, Inc. (CVSI) operates two distinct business segments: a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors; and a drug development division focused on developing and commercializing CBD-based novel therapeutics utilizing CBD. The Company’s PlusCBD™ Oil products are sold at more than 5,500 retail locations throughout the U.S. and it is the top-selling brand of hemp-derived CBD on the market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. CV Sciences’ state-of-the-art facility follows all guidelines for Good Manufacturing Practices (GMP) and the Company’s full spectrum hemp extracts are processed, produced, and tested throughout the manufacturing process to confirm the cannabinoid content meets strict company standards. With a commitment to science, PlusCBD™ Oil’s benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. PlusCBD™ Oil was the first hemp CBD supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. CV Sciences, Inc. has primary offices and facilities in San Diego, California. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
I'll enter at 19,223,000
I haven't proposed a valuation so there's nothing for me to justify. You have proposed a valuation and you won't defend it.
You simply haven't done the research and are just winging it.
You're the one proposing a valuation, yet you won't justify it because you haven't done the research.
Bye.
I'm not the one trying to do something outside the norm for such a stable, growing company, also so far apart from its peerset. Nice try to put me on defense though.
Show your numbers. This company isn't a typical weed company.
I don't care what you've been investing in or not for x years. Comments are based on the validity of their merit, not your hypothetical historical trading (that no one cares about).
Justify your valuation criteria with research please.
Mhmmmmm, no one can take you seriously if you are valuing this company based on quarterly earnings. Frankly, if you're going to fight to argue that this company should be valued on quarterly earnings - show some precedent of profitable, top market-performing, multi-year growth companies in emerging industries.
We'll sit here and wait for your comps. And please provide links. LOL
Good point about Gardner being up for reelection. Let's hope this thing gets passed!
The market uses annual numbers for valuations, not quarterly.
Can everyone shut up already about "pr pieces" and "management needs to do more"? It's the OTC! Do most of you have ANY experience investing or what? No matter what company it is, as long as its on the OTC, manipulation and volatility will rule supreme over it.
Period. End of story. People have no business investing in an OTC stock if they don't know this and factor it into your strategy.
Get it through your heads.
The best thing management can do, and any OTC company, is produce meaningful news (mostly done rarely in ANY company), keep increasing earnings quarter-on-quarter and keep working to get this uplisted onto NASDAQ (which will only happen once FDA clears up the national regulatory ambiguity).
Geeeeeeeesh - get a clue people.
You sound like you're a short-term trader caught in the recent downward slide and are frustrated at not seeing big stock moves quickly.
This is a solid company, on the OTC - it of course is going to be manipulated. The OTC is the wild wild west.
As an investor, it's your job to know this and plan your timeline and/or milestones or exit accordingly.
Companies on the OTC trade a lot less rationally than companies on the big boards.
Shooting off frivolous PRs and trying to artificially inflate the stock price by forcing press or news, only makes the company look amateurish.
Only legitimate news moves the stock price and only legitimate news should be put out by the company. At this point, they have done a good job of announcing new distribution deals and updating investors on all material company developments.
Just look towards quarterly earnings reports.